This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Natera's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $9.4. Natera's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-24), Natera's share price is $91.04. Natera's Median PS Value is $0.00. Therefore, Natera's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Natera's Median PS Value or its related term are showing as below:
NTRA's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.825 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Natera Median PS Value Historical Data
The historical data trend for Natera's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera Price-to-Median-PS-Value Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Natera's Price-to-Median-PS-Value falls into.
Natera Median PS Value Calculation
Natera's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Natera's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.4.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (NAS:NTRA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Natera's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
91.04
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera Median PS Value Related Terms
Thank you for viewing the detailed overview of Natera's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 